Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for N5749R100 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 2
|
0% |
2/17/2026
Event 12/31/2025
|
|
| Paradigm BioCapital Advisors LP | 0% | ||
| Paradigm BioCapital Advisors GP LLC | 0% | ||
| Senai Asefaw, M.D. | 0% | ||
| Paradigm BioCapital International Fund Ltd. | 0% | ||
|
Genmab A/S
13D/A
Amendment 1
|
0% |
12/30/2025
Event 12/30/2025
|
|
| Genmab A/S | 0% | ||
| Genmab Holding II B.V. | 0% | ||
|
Genmab A/S
13D
|
94.8% |
12/19/2025
Event 12/12/2025
|
|
| Genmab A/S | 94.8% | ||
| Genmab Holding II B.V. | 94.8% | ||
|
RTW Investments, LP
13G/A
Amendment 1
|
2.7% |
11/14/2025
Event 9/30/2025
|
|
| RTW Investments, LP | 2.7% | ||
| Roderick Wong | 2.7% | ||
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 1
|
6.2% |
11/14/2025
Event 9/30/2025
|
|
| Paradigm BioCapital Advisors LP | 6.2% | ||
| Paradigm BioCapital Advisors GP LLC | 6.2% | ||
| Senai Asefaw, M.D. | 6.2% | ||
| Paradigm BioCapital International Fund Ltd. | 5.4% | ||
|
Wellington Management Group LLP
13G/A
Amendment 3
|
0.6% |
11/12/2025
Event 9/30/2025
|
|
| Wellington Management Group LLP | 0.6% | ||
| Wellington Group Holdings LLP | 0.6% | ||
| Wellington Investment Advisors Holdings LLP | 0.6% | ||
|
FMR LLC
13G/A
Amendment 1
|
3.7% |
11/5/2025
Event 9/30/2025
|
|
| FMR LLC | 3.7% | ||
| Abigail P. Johnson | 3.7% | ||
|
Commodore Capital LP
13G/A
Amendment 1
|
4.7% |
8/14/2025
Event 6/30/2025
|
|
| Commodore Capital LP | 4.7% | ||
| Commodore Capital Master LP | 4.7% | ||
|
Wellington Management Group LLP
13G/A
Amendment 2
|
5.0% |
8/12/2025
Event 6/30/2025
|
|
| Wellington Management Group LLP | 5.0% | ||
| Wellington Group Holdings LLP | 5.0% | ||
| Wellington Investment Advisors Holdings LLP | 5.0% | ||
|
Wellington Management Group LLP
13G/A
Amendment 1
|
6.8% |
5/12/2025
Event 3/31/2025
|
|
| Wellington Management Group LLP | 6.8% | ||
| Wellington Group Holdings LLP | 6.8% | ||
| Wellington Investment Advisors Holdings LLP | 6.8% | ||
| Wellington Management Company LLP | 6.5% | ||
|
Paradigm Biocapital Advisors LP
13G
|
5.1% |
4/10/2025
Event 4/3/2025
|
|
| Paradigm BioCapital Advisors LP | 5.1% | ||
| Paradigm BioCapital Advisors GP LLC | 5.1% | ||
| Senai Asefaw, M.D. | 5.1% | ||
| Paradigm BioCapital International Fund Ltd. | 4.6% | ||
|
Wellington Management Group LLP
13G
|
5.1% |
2/10/2025
Event 12/31/2024
|
|
| Wellington Management Group LLP | 5.1% | ||
| Wellington Group Holdings LLP | 5.1% | ||
| Wellington Investment Advisors Holdings LLP | 5.1% | ||
|
Commodore Capital LP
13G
|
5.5% |
12/16/2024
Event 12/9/2024
|
|
| Commodore Capital LP | 5.5% | ||
| Commodore Capital Master LP | 5.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q4 | 10 | 89.4 k | $5.73 M |
| 2025 Q3 | 298 | 72.1 M | $6.78 B |
| 2025 Q2 | 222 | 75.1 M | $3.95 B |
| 2025 Q1 | 197 | 70.9 M | $2.99 B |
| 2024 Q4 | 203 | 70.4 M | $2.96 B |
| 2024 Q3 | 201 | 69.0 M | $3.45 B |
| 2024 Q2 | 196 | 69.3 M | $4.10 B |
| 2024 Q1 | 170 | 53.3 M | $2.40 B |
| 2023 Q4 | 143 | 52.0 M | $1.43 B |
| 2023 Q3 | 122 | 49.6 M | $1.12 B |
| 2023 Q2 | 120 | 41.3 M | $1.09 B |
| 2023 Q1 | 110 | 36.5 M | $672 M |
| 2022 Q4 | 97 | 36.8 M | $569 M |
| 2022 Q3 | 104 | 34.7 M | $694 M |
| 2022 Q2 | 95 | 35.3 M | $798 M |
| 2022 Q1 | 97 | 33.4 M | $884 M |
| 2021 Q4 | 108 | 33.3 M | $1.06 B |
| 2021 Q3 | 65 | 22.2 M | $488 M |
| 2021 Q2 | 71 | 27.2 M | $574 M |
| 2021 Q1 | 61 | 26.9 M | $562 M |
| 2020 Q4 | 45 | 22.0 M | $387 M |
| 2020 Q3 | 42 | 18.2 M | $218 M |
| 2020 Q2 | 44 | 18.6 M | $299 M |
| 2020 Q1 | 30 | 18.0 M | $218 M |
| 2019 Q4 | 40 | 17.9 M | $251 M |
| 2019 Q3 | 27 | 11.9 M | $212 M |
| 2019 Q2 | 27 | 11.8 M | $173 M |
| 2019 Q1 | 26 | 11.9 M | $175 M |
| 2018 Q4 | 28 | 12.1 M | $169 M |
| 2018 Q3 | 32 | 12.1 M | $239 M |
| 2018 Q2 | 27 | 14.3 M | $326 M |
| 2018 Q1 | 21 | 9.83 M | $182 M |
| 2017 Q4 | 17 | 5.90 M | $119 M |
| 2017 Q3 | 17 | 5.83 M | $116 M |
| 2017 Q2 | 17 | 6.31 M | $100 M |
| 2017 Q1 | 24 | 6.34 M | $155 M |
| 2016 Q4 | 11 | 4.86 M | $103 M |
| 2016 Q3 | 13 | 4.94 M | $82.3 M |
| 2016 Q2 | 16 | 4.81 M | $38.6 M |